Viral & Non-Viral Delivery
Delivery methods optimized for your payload, your target, and your path to the clinic.
// Viral & Non-Viral Delivery
Delivery Optimized for Scale and Manufacturability
Our delivery platforms span viral and non-viral approaches — lentiviral vectors, AAV, and lipid nanoparticles — giving partners the flexibility to match the right delivery method to their therapeutic target, payload, and development strategy. Each platform is supported by end-to-end process development and manufacturing capabilities, so partners can move from vector or formulation design through GMP production under one roof.
The LentiPeak™ Platform
The LentiPeak™ Platform
Our proprietary LentiPeak™ platform gives partners a suspension-based, scalable lentiviral vector production system designed for speed, control, and seamless transition from development to GMP manufacturing — supporting both ex vivo cell therapy programs and emerging in vivo gene therapies, including in vivo CAR-T.
What the platform delivers:
- Speed and flexibility with streamlined tech transfer between process development and cGMP with aligned unit operations, equipment, and analytics. Available capacity without extended wait times.
- Control and support with efficient supply chain management, comprehensive regulatory support, and integrated analytical testing panels built into the platform.
- Expertise and robust systems with a third-generation lentiviral system on a HEK 293 suspension cell line with proven performance across CAR and TCR constructs at multiple production scales.
Adeno-Associated Virus (AAV)
Our AAV platform supports partners from vector optimization through GMP manufacturing across multiple serotypes and therapeutic applications.
What partners get access to:
- Vector optimization including design and construct optimization to improve expression and manufacturability.
- Scalable GMP manufacturing with flexible production systems designed to support programs from early clinical supply through commercial scale.
- Integrated analytics with in-house characterization including potency, identity, and purity testing to support regulatory filings.
Lipid Nanoparticle (LNP) Delivery
Our proprietary LNP platform provides a non-viral delivery option for gene editing therapies and other genetic medicines requiring precise, targeted delivery. The platform has demonstrated targeted delivery of gene editing systems to the liver with high precision and low immunogenicity in preclinical models, with potential for repeat dosing across therapeutic applications.
What the platform offers:
- Targeted and de-targeted delivery with liver-targeting capabilities paired with the ability to bypass the liver and reach other tissue types.
- Repeat dosing potential with a low immunogenicity profile that supports multi-dose therapeutic strategies.
- Compatibility with our gene editing portfolio, designed to work with our compact nucleases, sized for efficient LNP encapsulation.
- Non-viral flexibility creating an alternative delivery option for programs where viral vectors present packaging, immunogenicity, or manufacturing constraints.
Partner with ElevateBio®
Wherever you are in your advanced therapy product lifecycle, we can strengthen and accelerate your development journey with our enabling technologies and unmatched process development and manufacturing capabilities.
// Work with us
